Le Lézard
Classified in: Business
Subject: ATY

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - VTYX


NEW YORK, April 20, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX) and certain officers.  The class action, filed in the United States District Court for the Southern District of California, and docketed under 24-cv-00415,  is on behalf of all persons and entities other than Defendants who purchased or otherwise acquired: (a) Ventyx common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about October 21, 2021 (the "IPO" or "Offering"); and/or (b) Ventyx securities between October 21, 2021 and November 6, 2023, both dates inclusive (the "Class Period").  Plaintiff pursues claims against the Defendants under the Securities Act of 1933 (the "Securities Act") and the Securities Exchange Act of 1934 (the "Exchange Act").

If you are a shareholder who purchased or otherwise acquired (a) Ventyx common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company's initial public offering; and/or (b) Ventyx securities during the Class Period, you have until April 30, 2024, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Danielle Peyton at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

[Click here for information about joining the class action]

Ventyx is a clinical-stage biopharmaceutical company that develops small-molecule product candidates to address a range of inflammatory diseases.  The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.  In 2022, Ventyx initiated a Phase 2 clinical trial of VTX958 for the treatment of moderate to severe plaque psoriasis (the "Phase 2 SERENITY Trial").

On September 29, 2021, Ventyx filed a registration statement on Form S-1 with the Securities and Exchange Commission ("SEC") in connection with the IPO, which, after several amendments, was declared effective by the SEC on October 20, 2021 (the "Registration Statement").

On October 21, 2021, Ventyx filed a prospectus on Form 424B4 with the SEC in connection with the IPO, which incorporated and formed part of the Registration Statement (the "Prospectus" and, collectively with the Registration Statement, the "Offering Documents").

The complaint alleges that the Offering Documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation.  In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.  Specifically, the Offering Documents and Defendants made false and/or misleading statements and/or failed to disclose that: (i) VTX958 was less effective in treating psoriasis than Defendants had led investors to believe; (ii) as a result, VTX958's clinical and/or commercial prospects were overstated; (iii) accordingly, the Company had misrepresented its ability to develop and commercialize effective product candidates; (iv) Ventyx's post-IPO business prospects were thus inflated; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

On November 6, 2023, during after-market hours, Ventyx issued a press release announcing results from the Phase 2 SERENITY Trial.  Therein, the Company disclosed that "[a]lthough the trial achieved its primary endpoint, the magnitude of efficacy observed did not meet our internal target to support the advancement of VTX958 in plaque psoriasis."  Based on these results, the Company announced that it "will terminate ongoing activities in the Phase 2 plaque psoriasis trial effective immediately" and "terminate the ongoing Phase 2 trial of VTX958 in psoriatic arthritis."

On this news, Ventyx's common stock price fell $11.36 per share, or 80.62%, to close at $2.73 per share on November 7, 2023.

Then, on November 22, 2023, Ventyx disclosed in a filing with the SEC on Form 8-K that the Company's President and Chief Medical Officer Defendant William J. Sandborn would cease to serve in those roles.

As of the time this Complaint was filed, the price of Ventyx common stock continues to trade below the $16.00 per share Offering price, damaging investors.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP


These press releases may also interest you

at 12:59
Trading resumes in: Company: Turnium Technology Group Inc. TSX-Venture Symbol: TTGI All Issues: Yes Resumption (ET): 1:15 PM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company....

at 12:59
Comerica Bank encourages the public to bring paper documents and computer electronic devices for recycling, free of charge, to Comerica's Great Lakes Campus (36455 Corporate Drive, Farmington Hills, MI 48331) on Saturday, June 15, from 8 a.m. to 1...

at 12:58
NEW YORK, May 30, 2024 Pomerantz LLP is investigating claims on behalf of investors of Sea Limited ("Sea" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....

at 12:57
Wizehire, a leading hiring solution, announced its Candidate Texting feature today. This new functionality enables organizations to instantly build stronger relationships with top talent, increase engagement, and streamline the hiring process....

at 12:57
As inclusion and the employee experience continue to gain traction amid rapidly shifting organizational priorities, inclusive language plays a key role in enabling workplaces where everyone...

at 12:45
GameChange Solar, a leading global supplier of solar mounting and tracking solutions for ground-mounted PV plants, has seen a significant surge in interest in its fixed-tilt racking systems over the past year. Several key factors drive the growing...



News published on and distributed by: